Responses
Late-breaking abstracts
Clinical trials completed
797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)
Compose a Response to This Article
Other responses
No responses have been published for this article.